Best in Biotech 20 Dec 2021 The Billion-Euro European Biotech Companies in 2022 Here’s a list of the public European biotech companies that are worth more than a billion euros in 2022. European biotech is growing steadily and this year we welcome a few new names to the list of billion-euro biotechs. However, we also had to say goodbye to some of them, including Cellectis, Autolus, and Orchard […] December 20, 2021 - 12 minutesmins - By Larissa Warneck-Silvestrin Share WhatsApp Twitter Linkedin Email
Best in Biotech 28 Dec 2020 A Year to Remember: The Biggest European Biotech News in 2020 The Covid-19 pandemic caused huge disruption for European biotech in 2020, but the industry pulled through. Let’s look back at some of the top moments in the last 12 months. After the many drug approvals, startup foundations, and venture capital highs we saw in 2019, it looked like 2020 was going to be a comfortable […] December 28, 2020 - 12 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 21 Apr 2020 Idorsia’s Drug Improves Sleep in First Phase III Trial for Insomnia The Swiss pharmaceutical company Idorsia has announced that its drug candidate daridorexant significantly improved sleep onset, sleep quality, and daytime functioning of insomnia patients in a pivotal phase III trial. The trial recruited 930 adult patients with insomnia. The company used a technique called polysomnography to measure the time taken to fall asleep and sleep […] April 21, 2020 - 3 minutesmins - By Karen O’Hanlon Cohrt Share WhatsApp Twitter Linkedin Email
News and Trends 5 Sep 2019 Top Cardiology Biotech News from the ESC Conference 2019 Many cardiology companies and academics gathered in Paris earlier this week to showcase their latest research into cardiovascular diseases. Read on for a roundup of the most exciting cardiology news from the biotech scene. The European Society of Cardiology teamed up with the World Heart Federation this year to arrange a conference themed on global […] September 5, 2019 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Best in Biotech 21 May 2019 The Top 20 Women in Leading Biotech Roles in Europe The biotech industry has often been criticized for its lack of gender diversity. While there is still a long way to go to achieve ideal levels of equality, there are more and more women filling leading roles in companies across Europe. Here are 20 women making an impact in the European biotech industry. Diversity comes […] May 21, 2019 - 12 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 18 Jun 2018 Swiss Biotech Tackles Brain Artery Constriction Caused by Hemorrhage Idorsia will start a Phase III trial to study the efficacy of its drug in treating the constriction of arteries in the brain caused by release of chemicals linked to a previous bleed in this area. The Swiss biotech Idorsia will test the efficacy of its drug, clazosentan, for treating patients whose brain arteries have […] June 18, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 16 May 2018 Actelion’s Billion-Euro Spin-Off Starts First Phase III Trial in its Pipeline Idorsia has started the first Phase III study in its pipeline to test the drug in patients with a life-threatening genetic disorder, which could bring the company closer to a market launch and profitability. Swiss biotech Idorsia has started a Phase III trial testing its lead compound in patients with Fabry disease, a life-threatening genetic disorder […] May 16, 2018 - 3 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
Best in Biotech 8 Mar 2018 Say Hello to the Top 14 Entrepreneurial Women in European Biotech Today, March 8, is international women’s day. To celebrate the achievements of women we’re revisiting our list of the women that have founded some of the hottest biotechs in Europe. Once upon a time, you would have been hard pushed to find a woman in a senior position at a top biotech – now, they […] March 8, 2018 - 8 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 1 Mar 2018 How is Actelion Spin-Off Idorsia Doing One Year Later? Actelion’s spin-off Idorsia was blessed with a large pipeline and a healthy bank balance. How has the biotech’s first year of business gone? Just over a year ago, Actelion, the largest biotech in Europe at the time, was snapped up by Johnson & Johnson for a massive €27.9Bn. “This deal is unique: J&J gets its […] March 1, 2018 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 20 Dec 2017 Actelion Spin Out and Roche Join Forces to Develop Cancer Immunotherapies Idorsia and Roche have agreed on a research collaboration, with the big pharma getting exclusive rights to develop and license resultant cancer immunotherapy drugs. Idorsia was formed out of J&J’s acquisition of Actelion for €27.9B at the beginning of the year. The spin out, led by Jean-Paul and Martine Clozel, kept hold of Actelion’s drug discovery and early […] December 20, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 4 Dec 2017 Swiss Biotech Brings in Reinforcements to See Hypertension Drug Through Phase III Idorsia will collaborate with Janssen on the development of its hypertension drug, aprocitentan, which could help to prevent future heart attacks and strokes. Idorsia was born out of Actelion’s massive $30B (€27.9B) acquisition by Johnson & Johnson, retaining all of the former biotech’s early-stage assets. The company develops small molecules for a broad range of […] December 4, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email